For the quarter ending 2025-09-30, INKT made $323,089 in revenue. -$2,860,505 in net income. Net profit margin of -885.36%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 1,143,178 | 1,839,176 | ||
| General and administrative | 1,846,495 | 1,849,130 | ||
| Change in fair value of related party note | 193,921 | 364,090 | ||
| Operating loss | -3,183,594 | -4,052,396 | ||
| Interest income, net | 55,151 | 348 | ||
| Other income (expense), net | 240,734 | -185,703 | ||
| Net loss | -2,887,709 | -4,237,751 | ||
| Foreign currency translation gain (loss) | 27,204 | -56,877 | ||
| Comprehensive loss | -2,860,505 | -4,294,628 | ||
| Earnings per share, basic | -0.65 | -1.06 | ||
| Earnings per share, diluted, total | -0.65 | -1.06 | ||
| Weighted average number of shares outstanding, basic | 4,443,262 | 3,981,992 | ||
| Weighted average number of shares outstanding, diluted, total | 4,443,262 | 3,981,992 | ||
MiNK Therapeutics, Inc. (INKT)
MiNK Therapeutics, Inc. (INKT)